BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 30655153)

  • 1. Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders in Cystic Fibrosis Lung Transplant Recipients: A Case Series.
    Mendogni P; Henchi S; Morlacchi LC; Tosi D; Nosotti M; Tarsia P; Gregorini AI; Rosso L
    Transplant Proc; 2019; 51(1):194-197. PubMed ID: 30655153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
    Hu J; Yu YW; Han DS; Li XJ; Zhang YQ; Cai HL; Xiao YH; Zheng X
    Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of PTLD in lung transplant recipients with cystic fibrosis.
    Lowery EM; Adams W; Grim SA; Clark NM; Edwards L; Layden JE
    J Cyst Fibros; 2017 Nov; 16(6):727-734. PubMed ID: 28456611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Epstein-Barr virus status and immunophenotypic studies in the evaluation of exfoliative cytology specimens from patients with post-transplant lymphoproliferative disorders.
    Gibson SE; Picarsic J; Swerdlow SH; Pantanowitz L
    Cancer Cytopathol; 2016 Jun; 124(6):425-35. PubMed ID: 26992116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
    Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute cellular rejection and Epstein-Barr virus-related post-transplant lymphoproliferative disorder in a pediatric lung transplant with low viral load.
    Calabrese F; Loy M; Lunardi F; Marino D; Aversa SM; Rea F
    Transpl Infect Dis; 2010 Aug; 12(4):342-6. PubMed ID: 20030794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus-associated smooth muscle tumors after lung transplantation.
    Hirama T; Tikkanen J; Pal P; Cleary S; Binnie M
    Transpl Infect Dis; 2019 Jun; 21(3):e13068. PubMed ID: 30864272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease.
    Verschuuren E; van der Bij W; de Boer W; Timens W; Middeldorp J; The TH
    J Med Virol; 2003 Feb; 69(2):258-66. PubMed ID: 12683416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
    Courtwright AM; Burkett P; Divo M; Keller S; Rosas IO; Trindade A; Mody GN; Singh SK; El-Chemaly S; Camp PC; Goldberg HJ; Mallidi HR
    Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients.
    Baldanti F; Rognoni V; Cascina A; Oggionni T; Tinelli C; Meloni F
    Virol J; 2011 Sep; 8():421. PubMed ID: 21892950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
    Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
    Aris RM; Maia DM; Neuringer IP; Gott K; Kiley S; Gertis K; Handy J
    Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1712-7. PubMed ID: 8970360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients.
    Levine SM; Angel L; Anzueto A; Susanto I; Peters JI; Sako EY; Bryan CL
    Chest; 1999 Nov; 116(5):1273-7. PubMed ID: 10559086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients.
    Capello D; Rasi S; Oreste P; Veronese S; Cerri M; Ravelli E; Rossi D; Minola E; Colosimo A; Gambacorta M; Muti G; Morra E; Gaidano G
    J Pathol; 2009 Aug; 218(4):478-86. PubMed ID: 19391128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.
    Mamzer-Bruneel MF; Lomé C; Morelon E; Levy V; Bourquelot P; Jacobs F; Gessain A; Mac Intyre E; Brousse N; Kreis H; Hermine O
    J Clin Oncol; 2000 Nov; 18(21):3622-32. PubMed ID: 11054435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.